Sparsentan Treatment for IgA Kidney Disease in Switzerland
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study documents real-world experiences of patients in Switzerland taking sparsentan, a newer medication for IgA nephropathy (a type of kidney disease caused by immune deposits). The goal is to understand how well sparsentan works and how safe it is when used in everyday clinical practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with IgA nephropathy (a kidney condition where IgA protein builds up and damages the kidneys)
- You are currently taking or have taken sparsentan (a medication designed to protect the kidneys)
- You are 18 years old or older
- You are being treated in Switzerland or at a participating Swiss healthcare center
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called MY008211A for people with IgA nephropathy (a kidney disease). It aims to see if it can safely reduce protein in the urine and protect kidney function.
This trial tests a new medicine called SLN12140 for adults with IgA nephropathy, a kidney disease where the immune system damages the kidneys. The study aims to see if this medicine can slow kidney damage and reduce protein loss in urine.
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
This study continues treatment with an experimental medicine called HSK39297 for people with IgA nephropathy, a condition where the immune system damages the kidneys. The trial will track how safe and effective the medicine is over time in people who already completed an earlier study.
This trial tests whether finerenone can help people with IgA nephropathy, a kidney disease. It is for adults with high protein in their urine who are already on standard kidney-protecting medications.
This study observes how people with IgA nephropathy respond to standard and newer treatments in everyday medical practice, to understand why some cases are resistant to therapy.
Hear when a new IgA Nephropathy (IgAN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.